Pfizer, Inc. · NYSE:PFE

Pfizer — Leerink Partners Immuno-Oncology Roundtable 2015

15 slides from Pfizer's conference presentation, Oct 1, 2015

  1. Slide 1: Leerink Partners Immuno-Oncology Roundtable

    Leerink Partners Immuno-Oncology Roundtable. Pfizer Oncology Presentation October 1 2015 1 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

  2. Slide 2: Pfizer Oncology

    Pfizer Oncology Liz Barrett President, Pfizer Oncology October 1 2015 2 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements Our discussion during this presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates and our oncology strategy, including their potential benefits, and expected clinical trial study starts, regulator

  4. Slide 4: Pfizer's Oncology Strategy, Pipeline and Portfolio

    Pfizer's Oncology Strategy, Pipeline and Portfolio Pfizer Oncology: Targeting the Immune System: Today and in the Future A New Front in the War on Cancer Check point modulators Growing PD-L1 avelumab, 4-1BB, OX40 Product Line (Japan only) OX40 4-1BB 2 Today PD-1 PD-L1 4 Launches 4 Launches in 4 Years

  5. Slide 5: Pfizer Oncology: An Exciting Road Ahead

    Pfizer Oncology: An Exciting Road Ahead • Excellent uptake of Ibrance reaching over 12,000 patients since February 2015 launch • Our goal is to deliver 1-2 new product launches a year for next 3 years as well as potential indication expansions for Bosuilif, Xalkori and Ibrance • In addition, we will

  6. Slide 6: Immuno-Oncology

    Immuno-Oncology Chris Boshoff, VP, Early Development, Translational, & Immuno-Oncology 6 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

  7. Slide 7: Pfizer Is Focused on a Multi-Pronged Approach to IO

    Pfizer Is Focused on a Multi-Pronged Approach to IO Advance Focused Single Agent Program • Accelerated development for target tumors: Focused PD1, PDL1, 41BB Single • Enable rapid advancement to combination strategies Agent Program Breadth and Depth of Our Portfolio Offers Potential for Several IO C

  8. Slide 8: Pfizer's Pipeline Targets Multiple Immune Mechanisms

    Pfizer’s Pipeline Targets Multiple Immune Mechanisms Epithelial Checkpoint inhibitors cell • Anti-PD-L1 avelumab (Ph 3 with Merck KGaA) • Anti-PD-1 PF-06801591 (IND ‘15) CD8+ effector T cell Activate T cells Tumor • CD137/4-1BB (Ph 1) cells • OX-40 agonist antibody (Ph 1) Deplete Treg cells • CCR4 a

  9. Slide 9: Rational Combinations

    Rational Combinations Our Immunotherapy Portfolio Our Kinase Inhibitors Chemotherapy Inlyta External Combos (axitinib) OX40 mAb KHK: CCR4 mAb KEYTRUDA XALKORI (crizotinib) gedatolisib 4-1BB mAb PI3K/mTOR Faslodex avelumab EGFR T790M letrozole IBRANCE (palbociclib) IMBRUVICA CCR2i glasdegib / SMO tas

  10. Slide 10: Avelumab (anti-PD-L1)

    Avelumab (anti-PD-L1) Potential to Elicit Antibody -Mediated Cell Cytotoxicity (ADCC) Key Competitors DURVALUMAB ATEZOLIZUMAB OPDIVO KEYTRUDA 10 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

  11. Slide 11: JAVELIN Solid Tumor: Phase I Study 2015 (EMR 100070-001)

    • The JAVELIN Clinical Trial Program is assessing the safety and efficacy of Avelumab across multiple tumor types • >1,000 patients treated as part of multicenter, dose-escalation and parallel-group, dose-expansion phase I trial (NCT01772004; JAVELIN Solid Tumor) • Avelumab efficacy and safety are b

  12. Slide 12: JAVELIN Clinical Development Program Across 15 Tumor Types

    JAVELIN Clinical Development Program Across 15 Tumor Types Ongoing Trials Trials initiating over next 6 months (as of October 1,2015) (October 2015 – March 2016) • Progress year-to-date represents robust program avelumab monotherapy: avelumab + Inlyta across more than 15 tumor JAVELIN solid tumor tr

  13. Slide 13: CD137/4-1BB Mechanism of Action

    CD137/4-1BB Mechanism of Action Urelumab (BMS 663513) • IgG4; t1/2~8-12h; Q3W • Does not block natural ligand PF-05082566 • IgG2; t1/2 ~ 10h; Q4W • Ligand binding blocker 13 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

  14. Slide 14: Rituxan + PF-2566 Durable CR in Heavily Pretreated R-refractory FL

    Rituxan + PF-2566 Durable CR in Heavily Pretreated R-refractory FL Screen Month 2 0.12 mg/kg PF-2566 Date of Bendamustine PF-2566 Diagnosis RCVP Rituxan Rituxan Rituxan Idelalisib Bexxar +Rituxan 2/09 3/09 6/09 7/09 6/10 11/10 4/11 8/11 11/11 6/12 11/12 6/13 CR PD PR PD PR PD PD CR >26 mo 14 DRAFT –

  15. Slide 15: Thank You

    Thank You 15 DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only

Pfizer — Leerink Partners Immuno-Oncology Roundtable 2015 on 6ix